

HOT TOPICS ASBMR 2021

Miércoles 17 de noviembre de 2021, Reunión Virtual

16:00 – 16:05 ***Presentación del curso***
Dr. José A. Riancho Moral, Dra. Pilar Peris Bernal

PRIMER BLOQUE

16:05 – 16:25 ***Riesgo de fractura: algoritmos de valoración, impacto de la pandemia por Covid-19 y papel de las vacaciones terapéuticas.***
Dr. José L. Pérez Castrillón

16:25 – 16:45 ***Prevención secundaria de la fractura. Utilidad de la densitometría ósea en la valoración del riesgo de fractura.***
Dra. Cristina Carbonell Abella

16:45 - 17:05 ***¿Son aconsejables las vacaciones terapéuticas en el tratamiento prolongado con bisfosfonatos?***
Dr. Carlos Gómez Alonso

17:05 – 17:15 ***Discusión***

SEGUNDO BLOQUE

17:15 - 17:35 ***Novedades en el tratamiento de las enfermedades raras.***
Dr. Guillermo Martínez Díaz-Guerra

17:35 - 17:55 ***Una mirada al futuro: avances en inteligencia artificial y fármaco-epidemiología.***
Dr. Luis Del Rio Barquero

17:55 – 18:15 ***Células progenitoras esqueléticas: papel funcional y terapéutico potencial.***
Dra. Arancha Rodríguez de Gortázar

18:15– 18:25 ***Discusión***

18:25 - 18:40 ***Pausa***

TERCER BLOQUE

- 18:40 – 19:00** *Tratamiento secuencial secuencial en la osteoporosis y su aplicación a la discontinuación de denosumab.*
Dra. Nuria Guañabens Gay
- 19:00 – 19:20** *Guías de práctica clínica en el hipoparatiroidismo e hiperparatiroidismo primario.*
Dr. Esteban Jodar Gimeno
- 19:20 – 19:40** *El futuro de la regeneración tisular.*
Dr. Manuel Naves Díaz
- 19:40 – 19:50** *Discusión*

CUARTO BLOQUE

- 19:50 – 20:10** *Nuevas funciones del FGF-23.*
Dr. Manuel Muñoz Torres
- 20:10-20:30** *Situación actual de la genética molecular en la patología metabólica ósea.*
Dr. Xavier Nogués Solán
- 20:30 - 20:50** *Enfermedad renal crónica, bisfosfonatos y vitamina D.*
Dra. Minerva Rodríguez García.
- 20:50– 21:00** *Discusión y clausura del curso*



Los HOT TOPICS son una iniciativa de
SEIOMM con el patrocinio de:



Además de las ponencias y sesiones plenarias que se muestran en el programa, los ponentes comentarán en su presentación varias comunicaciones orales y posters plenarios que se han seleccionado por su interés científico. Este listado de comunicaciones y posters es tentativo y podría variar ligeramente en función del tiempo de exposición del ponente o la no adecuación del mismo para su presentación.

Listado comunicaciones orales y sesiones plenarias seleccionadas: (en Rojo: sesiones plenarias y/o mesas, en Negro: comunicaciones)

CRISTINA CARBONELL ABELLA

Joint ASBMR-IOF Special Session: Closing the Gap in Secondary Fracture Prevention:

ASBMR Secondary Fracture Prevention Initiative, October 1, 12:00 PM-12:30 PM; Ballroom 6C.

IOF Capture the Fracture Partnership, October 1, 12:30 PM-01:00 PM; Ballroom 6C.

[FRI-260] Anabolic Response to PTH differs by both genetic and sex effects. October 1, 05:00 PM-06:30 PM; Sails Pavilion.

[LB VPP - 841] Repeat Bone Mineral Density Measurement and Fracture Prediction in Older Men: Findings from the Osteoporotic Fractures in Men (MrOS) Study. October 2, 07:00 AM-05:00 PM.

[1056] Validation of the Surrogate Threshold Effect as a Method to Implement Change in BMD as a Surrogate Endpoint for Fracture Outcomes: the FNIIH-ASBMR SABRE Project. October 3, 10:00 AM-10:15 AM; Ballroom 6AB.

LUIS DEL RIO BARQUERO

Symposium: A Look to the Future: Advances and Challenges in Clinical Bone Research:

Novel Big Data Approaches to Pharmacoepidemiology in Bone Health, October 2, 03:15 PM-03:40 PM; Ballroom 6AB/San Diego Convention Center.

A Look to the Future: Advances and Challenges in Clinical Bone Research Artificial Intelligence and Imaging for an Integrated Approach to Musculoskeletal Aging, October 2, 03:40 PM-04:05 PM; Ballroom 6AB.

The global LMIC Osteoporosis Explosion: Can We Change the Future? October 2, 04:05 PM-04:30 PM; Ballroom 6AB.

[1027] Artificial intelligence-driven hip fracture prediction based on pelvic radiographs exceeds performance of DXA: the “Study of Osteoporotic Fractures” (SOF). October 2, 10:15 AM-10:30 AM; Ballroom 6DE.

[1097] Rapid Cortical Bone Loss Is Associated with Higher Fracture Risk in Older Men – the STRAMBO Study. October 4, 10:00 AM-10:15 AM.

CARLOS GOMEZ ALONSO

ASBMR/ECTS Clinical Debate: Intermittent Drug Holidays Are Mandatory for Long Term Bisphosphonate Treatment of Osteoporosis? October 01, 2021, 03:15 PM; Ballroom 6AB

[1058] Targeted high-intensity exercise with and without antiresorptive medication to increase bone strength and reduce fracture risk in postmenopausal women: the MEDEX-OP trial. October 3, 10:30 AM-10:45 AM; Ballroom 6AB.

[1096] Strong discordance in factors associated with 5-year risk of fracture vs. 5-year risk of mortality among men aged 80 and older: findings from the Osteoporotic Fractures in Men [MrOS] study. October 4, 09:45 AM-10:00 AM; Ballroom 6AB.

[LB - 1115] Etelcalcetide improves central skeleton bone density and quality in patients on dialysis. October 4, 12:00 PM-12:15 PM; Ballroom 6AB.

NURIA GUAÑABENS GAY

[FRI-266] Skeletal Disease Acquisition in Fibrous Dysplasia: Natural History and Indicators of Lesion Progression. October 1, 05:00 PM-06:30 PM; Sails Pavilion.

[FRI-267] Inhibition of IL-6 in the Treatment of Fibrous Dysplasia of Bone: the Randomized Placebo-Controlled TOCIDYS Trial. October 1, 05:00 PM-06:30 PM; Sails Pavilion.

[1057] Real-world Pattern of Anabolic Agents and Sequential Antiresorptive Drug Use. October 3, 10:15 AM-10:30 AM; Ballroom 6AB.

[1072] Sequential Treatment with Zoledronate Prevents Rebound Bone Loss Following Withdrawal of RANKL Inhibition. October 3, 03:30 PM-03:45 PM; Ballroom 6F.

[1078] Dual Anti-Resorptive and Anabolic Effect of Bone-Target-Hydroxychloroquine for the Prevention and Treatment of Osteoporosis. October 3, 03:45 PM-04:00 PM; Ballroom 6AB.

[1080] Low osteoblast number and OPG levels may contribute to rebound resorption after discontinuation of Denosumab administration. October 3, 04:15 PM-04:30 PM; Ballroom 6AB.

[1086] Osteoclast-derived IGF1 alters osteocyte function and is an important contributor to the development of Paget's disease. October 4, 09:45 AM-10:00 AM; Ballroom 6C.

ESTEBAN JODAR GIMENO

Late-Breaking Oral Presentation: Clinical Hyperparathyroidism and Hypoparathyroidism Guidelines:

[LB - 1101] Guidelines on Diagnosis, Evaluation and Management of Hypoparathyroidism: 2021. October 3, 11:45 AM-12:15 PM; Ballroom 6AB

[LB - 1102] Guidelines on Diagnosis, Evaluation, and Management of Primary Hyperparathyroidism, 2021. October 3, 12:15 PM-12:45 PM; Ballroom 6AB.

[1100] Divergent patterns of anti-fracture medication use following fracture on therapy: A registry-based cohort study. October 4, 10:45 AM-11:00 AM; Ballroom 6AB.

[LB - 1113] Vamorolone, a first-in-class dissociative steroid, is associated with improved muscle strength and favourable bone and growth plate profiles in young boys with ambulatory Duchenne Muscular Dystrophy. October 4, 11:30 AM-11:45 AM; Ballroom 6AB.

[LB - 1117] Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk: an FNII-ASBMR SABRE study pooled analysis. October 4, 12:30 PM-12:45 PM; Ballroom 6AB.

GUILLERMO MARTINEZ DIAZ-GUERRA

[1016] Setrusumab for the Treatment of Osteogenesis Imperfecta (OI): Results from the Phase 2b ASTEROID Study. October 1, 01:30 AM-01:45 PM; Ballroom 6AB.

[1017] Targeting Transforming Growth Factor- β (TGF- β) for Treatment of Osteogenesis Imperfecta. October 1, 01:45 PM-02:00 PM; Ballroom 6AB.

[1019] Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva in Females Aged ≥ 8 Years and Males Aged ≥ 10 Years: Data From the Phase III Move Trial. October 1, 02:15 PM-02:30 PM; Ballroom 6AB.

[1020] Burosumab Improves Lower Limb Alignment in Children with X Linked Hypophosphatemia. October 1, 02:30 PM-02:45 PM; Ballroom 6AB.

[LB - 1120] Abaloparatide as a Novel Chondroregenerative Therapy for Posttraumatic Osteoarthritis. October 4, 12:00 PM-12:15 PM; Ballroom 6C.

[LB - 1121] Sclerostin antibody-induced peri-implant osseointegration in Osteogenesis Imperfecta mouse model. October 4, 12:15 PM-12:30 PM; Ballroom 6C.

MANUEL MUÑOZ TORRES

Cutting Edge Session: FGF23: Beyond Phosphate Metabolism:

New roles of FGF23 in Cardiovascular Outcomes and Iron Handling. October 2, 11:45 AM-12:15 PM; Ballroom 6C.

Effects of FGF23 Beyond Phosphorus Homeostasis. October 2, 12:15 PM-12:45 PM; Ballroom 6C.

[1022] A Brain Dependent Osteogenic Factor Controls Peak Bone Mass. October 2, 10:15 AM-10:30 AM; Ballroom 6F.

[1025] Bone Loss Following SARS-CoV-2 Infection in Mice. October 2, 11:00 AM-11:15 AM; Ballroom 6F.

[LB - 1118] Glucocorticoid Rhythm is Essential for Maintaining Bone Structure and Strength. October 4, 11:30 AM-11:45 AM. Ballroom 6C.

MANUEL NAVES DIAZ

Limb Regeneration Plenary Symposium:

Regenerative Engineering: The Future of Tissue Regeneration. October 4, 08:00 AM-08:25 AM; Ballroom 6AB.

Mammalian Digit Tip Regeneration: From Phenomenon to Molecular Mechanism. October 4, 08:25 AM-08:50 AM; Ballroom 6AB.

Learning from the axolotl's natural ability to regenerate limbs. October 4, 08:50 AM-09:15 AM; Ballroom 6AB.

[1003] Wnt/b-catenin signaling controls self-renewal and differentiation of growth plate chondroprogenitors. October 1, 02:00 PM-02:15 PM; Ballroom 6F.

[1075] LRRK1 Regulates Osteoclast Function Via Modulating Lysosomal Trafficking and Secretion. October 3, 04:15 PM-04:30 PM; Ballroom 6F.

[LB - 1107] Blockade of Immune Checkpoint Proteins Fuels Trabecular Bone Loss and Reduces Bone Toughness. October 4, 12:30 PM-12:45 PM; Ballroom 6F.

XAVIER NOGUES SOLAN

Louis V. Avioli Lecture: The Molecular Genetics Revolution: Promise Fulfilled? October 2, 08:00 AM-09:30 AM; Ballroom 6AB.

[FRI-237] A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass – An Interim Three-Month Analysis. October 1, 05:00 PM-06:30 PM; Sails Pavilion.

[1051] Prevalence of Monogenic Bone Disorders in a Dutch Cohort of AFF Patients. October 3, 10:00 AM-10:15 AM; Ballroom 6DE.

[1053] Identifying Causes of Fracture Independent of Bone Density: Evidence from Human Genetics. October 3, 10:30 AM-10:45 AM; Ballroom 6DE.

[LB - 1116] A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass – 6 Month Bone Mineral Density (BMD) results. October 4, 12:15 PM-12:30 PM; Ballroom 6AB. (continuación del Abstract FRI 237, unificar los resultados)

JOSE LUIS PEREZ CASTRILLON

ASBMR Task Force on Clinical Algorithms for Fracture Risk, October 01, 2021, 12:00 PM-Ballroom 6DE.

[1026] The impact of the first nation-wide Covid-19 lockdown on hip fractures in France. October 2, 10:00 AM-10:15 AM; Ballroom 6DE.

[1028] A Shorter Drug Holiday after 3 or More Years of Risedronate versus Alendronate is Important to Maintain Osteoporotic Fracture Protection: A Propensity-Score Matched Cohort Study. October 2, 10:30 AM-10:45 AM; Ballroom 6DE.

[1029] The Effect of Recent Fracture on 10-year Fracture Probability: A Registry-Based Cohort Study. October 2, 10:45 AM-11:00 AM; Ballroom 6DE

[LB - 1119] Bone anabolic effects of a novel, orally-available salt inducible kinase inhibitor. October 4, 11:45 AM-12:00 PM; Ballroom 6C.

ARANCHA RODRIGUEZ DE GORTAZAR

Basic Symposium: Skeletal Progenitors

Metabolism of Skeletal Progenitors: More than Bioenergetics. October 1, 03:15 PM-03:40 PM; Ballroom 6DE.

Functional Role and Therapeutic Potential of Vascular Niches in Bone. October 1, 03:40 PM-04:05 PM; Ballroom 6DE.

Intravital Identification of Niches. October 1, 04:05 PM-04:30 PM; Ballroom 6DE.

[1014] A Specialized Osteoblast Metabolic Pathway Deposits Citrate into Hydroxyapatite to Impact Bone Strength. October 1, 02:15 PM-02:30 PM; Ballroom 6C.

[1043] Hypoxia-inducible factor signaling in breast tumors controls site-specific dissemination to bone and lung. October 3, 10:30 AM-10:45 AM; Ballroom 6F.

[1061] Multi-Targeting DKK1 and LRP6 Prevents Myeloma-Induced Bone Disease. October 3, 03:15 PM-03:30 PM; Ballroom 6C.

[1065] Single-cell proteomic mapping of the aging bone microenvironment identifies a novel senescent osteoprogenitor population targeted by senolytic treatment. October 3, 04:15 PM-04:30 PM; Ballroom 6C.

MINERVA RODRIGUEZ GARCIA

[1032] Superior efficacy and safety of 1-year treatment with monthly calcifediol 0.266 mg soft capsules compared to monthly cholecalciferol 25,000 IU and effect of calcifediol withdrawal in 25(OH)D levels. October 2, 10:15 AM-10:30 AM; Ballroom 6C.

[1034] Supplemental Vitamin D Did Not Reduce Incident Fractures in Women and Men in the VITamin D and Omega-3 Trial (VITAL). October 2, 10:45 AM-11:00 AM; Ballroom 6C.

[1060] Renal Safety Of Zoledronic Acid In Patients With Borderline Kidney Function At A Metabolic Bone Centre In The United Kingdom. October 3, 11:00 AM-11:15 AM; Ballroom 6AB.

[LB - 1108] Hip Fractures: Initial Report of Trends in Incidence, Treatment, and Mortality In Multiple Countries Using a Common Analytical Platform. October 4, 11:30 AM-11:45 AM. Ballroom 6DE.

[LB - 1111] Effect of vitamin D replacement on maternal and neonatal outcomes: a randomized controlled trial in pregnant women with hypovitaminosis D. October 4, 12:15 PM-12:30 PM. Ballroom 6DE.

[LB - 1112] Severity of proteinuria is associated with incident fragility fractures in patients with chronic kidney disease independent of estimated glomerular filtration rate. October 4, 12:30 PM-12:45 PM.